Ascent Group’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
Other funds holding NVO
DAM
F
Ascent Group's NVO Position: Q1 2026 in Review
Ascent Group increased its Novo Nordisk (NVO) stake by 5.5% in Q1 2026, buying an estimated $21.5K and bringing the position to 8,683 shares worth $319K. The position accounts for 0.01% of the portfolio, ranked #607.
Ascent Group first reported a position in NVO in Q4 2021 and has held it in 18 quarters since. The position peaked at $3.26M in Q2 2024. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.
- Ascent Group held 8,683 shares of Novo Nordisk worth $319K as of Q1 2026.
- Ascent Group bought 453 Novo Nordisk shares in Q1 2026, an estimated $21.5K.
- Novo Nordisk made up 0.01% of Ascent Group's portfolio in Q1 2026, its #607 holding.
- Ascent Group first reported a position in Novo Nordisk in Q4 2021 and has held it in 18 quarters since.
- Ascent Group's Novo Nordisk position peaked at $3.26M in Q2 2024.
- 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.
Based on Ascent Group's 13F filing for Q1 2026, filed 15 May 2026.